High Cholesterol: What Is Happening in the Arteries?

September 10, 2026

A cholesterol result comes back as “high”, but the person sitting in front of you feels completely well. There is no pain, no breathlessness and usually nothing on examination that tells you cholesterol has been accumulating in the circulation for years.

Imagine Karen, 52, who has bloods taken during a routine cardiovascular review. Her total cholesterol is raised. She is surprised because she thought cholesterol was something you could feel when it became a problem. Her first question is simple: what is the cholesterol actually doing?

That question takes us beyond memorising “good” and “bad” cholesterol. Cholesterol itself is essential to normal physiology. The clinical problem is how cholesterol is transported in the blood, how long atherogenic lipoproteins are circulating, and what happens when cholesterol-rich particles become retained within the arterial wall.

Cholesterol is not the enemy. Transport is the important part.

Cholesterol is a lipid used in cell membranes and as a precursor for steroid hormones and bile acids. Because lipids do not dissolve freely in the watery environment of plasma, cholesterol and triglycerides travel through the circulation packaged inside lipoproteins.

Low-density lipoprotein (LDL) is one of these particles. LDL carries cholesterol through the circulation and delivers it to tissues. High-density lipoprotein (HDL) participates in transporting cholesterol away from peripheral tissues towards the liver. This is where the familiar labels “bad cholesterol” and “good cholesterol” come from, but they are useful only as a starting point. LDL is not a poisonous substance and HDL is not a protective medicine circulating in the blood.

The more important concept is exposure to cholesterol carried within atherogenic apolipoprotein B-containing particles, particularly LDL. Evidence from genetic studies, observational research and randomised trials supports LDL as a causal factor in atherosclerotic cardiovascular disease. Risk relates not only to how high LDL cholesterol is, but also to how long the arterial circulation is exposed to it.

This helps explain why a person with familial hypercholesterolaemia can develop cardiovascular disease at a much younger age. Their LDL cholesterol may have been markedly elevated since childhood rather than becoming raised only later in adult life.

How does cholesterol become an atherosclerotic plaque?

The artery is not simply a pipe that gradually fills with fat. Atherosclerosis develops within the arterial wall through a biological process involving lipoprotein retention, inflammation and changes in vascular cells.

Atherogenic lipoprotein particles, particularly LDL, can enter the arterial intima and become retained within the extracellular matrix. Modified lipoproteins promote an inflammatory response, attracting monocytes into the vessel wall. These differentiate into macrophages and take up lipid. As cholesterol accumulates, lipid-laden foam cells develop.

Over time, the lesion becomes more complex. Lipid, inflammatory cells, smooth-muscle cells and extracellular material contribute to an atherosclerotic plaque. A fibrous cap can form over a lipid-rich core. The clinical consequences depend on where disease develops and what happens to the plaque. Progressive narrowing can restrict blood flow, while disruption of a vulnerable plaque can expose thrombogenic material and trigger acute thrombus formation.

In a coronary artery, that process can produce an acute coronary syndrome and myocardial infarction. In arteries supplying the brain it can contribute to ischaemic stroke, and in peripheral arteries it can lead to peripheral arterial disease. Karen's cholesterol result therefore is not important because the number itself causes symptoms today. It matters because it contributes to her future vascular exposure and risk.

Reading a lipid profile without reducing it to one number

A full lipid profile gives more information than total cholesterol alone. It includes total cholesterol, HDL cholesterol and triglycerides, with non-HDL cholesterol and LDL cholesterol calculated by the laboratory. NICE does not require a fasting sample for a routine full lipid profile, although very high triglycerides may require repeat fasting measurement and further assessment.

Total cholesterol is the overall cholesterol concentration carried in the different lipoproteins. LDL cholesterol (LDL-C) estimates the cholesterol carried in LDL particles. HDL cholesterol (HDL-C) measures cholesterol carried in HDL particles. Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol and therefore captures cholesterol carried in several potentially atherogenic particles rather than LDL alone. Triglycerides are another circulating lipid and markedly raised concentrations have their own clinical implications.

For otherwise healthy adults, NHS information gives broad reference levels such as total cholesterol below 5 mmol/L and non-HDL cholesterol below 4 mmol/L, but these are not universal treatment targets. A cholesterol result must be interpreted alongside the person's cardiovascular history and overall risk.

That distinction is important. Two people can have the same cholesterol result but very different clinical decisions. A younger person without established cardiovascular disease may be having their future risk assessed. Someone who has already had a myocardial infarction, stroke or other atherosclerotic cardiovascular event is in secondary prevention, where lipid-lowering treatment is aimed at reducing the chance of another event.

In England and Wales, NICE recommends QRISK3 for estimating 10-year cardiovascular disease risk in many adults aged 25 to 84 without established cardiovascular disease. For primary prevention, atorvastatin 20 mg is offered when the 10-year QRISK3 score is 10% or more, while treatment should not automatically be ruled out below 10% where risk may be underestimated or the person makes an informed choice to take a statin. NICE uses different approaches for groups already known to be at high risk, including people with established cardiovascular disease, familial hypercholesterolaemia and some people with chronic kidney disease. Risk assessment and prescribing pathways differ across the UK, so students should follow the guidance and formulary used in their nation and local service.

When “high cholesterol” should make you look further

Not every raised cholesterol result is explained by diet, and immediately framing it as a lifestyle problem can miss clinically important information. Secondary causes of dyslipidaemia include uncontrolled diabetes, hypothyroidism, liver disease, nephrotic syndrome and excess alcohol intake. Medicines can also affect lipid levels.

Very high cholesterol should also raise the possibility of an inherited lipid disorder. Familial hypercholesterolaemia (FH) is an inherited condition in which LDL cholesterol is elevated from an early age, commonly because normal clearance of LDL from the circulation is impaired. The British Heart Foundation estimates that FH affects about 1 in 250 people.

NICE advises considering FH in adults with total cholesterol above 7.5 mmol/L or a personal or family history of premature coronary heart disease. Clinical assessment uses criteria such as Simon Broome or the Dutch Lipid Clinic Network score rather than diagnosing FH from one cholesterol result. Where a genetic diagnosis is established, cascade testing can identify biological relatives who may also have inherited the condition.

This changes the conversation with the patient. A fit young adult with markedly raised LDL cholesterol and a father who had a myocardial infarction in his forties does not simply need a lecture about takeaway food. The family history, degree of lipid elevation and duration of exposure may be the most important clues in the room.

Lowering cholesterol is really about lowering cardiovascular risk

Lifestyle measures remain part of cardiovascular prevention. These include supporting smoking cessation, physical activity, a balanced diet with less saturated fat, weight management where appropriate and alcohol advice. These conversations work best when they are individualised rather than presented as blame for a blood result. Genetics, age, comorbidity, medicines and socioeconomic circumstances can all influence cardiovascular risk.

Statins are the main pharmacological treatment for lowering LDL cholesterol. They inhibit hepatic cholesterol synthesis, which leads the liver to increase LDL receptor activity and remove more LDL particles from the circulation. Their purpose is not simply to make the laboratory number look better. Lowering LDL exposure reduces the risk of atherosclerotic cardiovascular events.

For primary prevention under NICE guidance, the treatment target for a person taking a statin is a reduction in non-HDL cholesterol of more than 40%. For secondary prevention, NICE recommends aiming for LDL cholesterol of 2.0 mmol/L or less, or non-HDL cholesterol of 2.6 mmol/L or less. People with established cardiovascular disease are generally offered high-intensity statin therapy irrespective of their starting cholesterol level.

Not everyone reaches an appropriate lipid target with a statin alone, and some people cannot tolerate an adequate statin dose. Depending on the indication and national or local pathway, additional lipid-lowering therapies can include ezetimibe, bempedoic acid, PCSK9 inhibitors such as alirocumab or evolocumab, and inclisiran. These drugs work through different mechanisms, but the clinical aim remains reduction of atherogenic lipid exposure and cardiovascular risk.

Nursing care includes more than checking whether the prescription has been taken. Before statin treatment, assessment may include the lipid profile, blood pressure, smoking and alcohol history, diabetes status, renal function, liver transaminases and thyroid testing when clinically indicated. NICE recommends repeating a full lipid profile and liver transaminases 2 to 3 months after starting or changing lipid-lowering treatment. Unexplained muscle pain, tenderness or weakness should be assessed rather than dismissed, although severe statin-related muscle injury is rare.

So when Karen asks what her raised cholesterol is doing, the answer is not that cholesterol is slowly “blocking her arteries” like grease in a drain. The more accurate explanation is that prolonged exposure to atherogenic lipoproteins can drive a chronic inflammatory process within arterial walls. Her blood result is one part of understanding that process, and one part of deciding how her future cardiovascular risk can be reduced.

References

Back to blog